ATE224713T1 - Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression - Google Patents
Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppressionInfo
- Publication number
- ATE224713T1 ATE224713T1 AT97928260T AT97928260T ATE224713T1 AT E224713 T1 ATE224713 T1 AT E224713T1 AT 97928260 T AT97928260 T AT 97928260T AT 97928260 T AT97928260 T AT 97928260T AT E224713 T1 ATE224713 T1 AT E224713T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridyl
- alkaneous
- tumors
- treatment
- immunosupression
- Prior art date
Links
- -1 ACIDS AMIDES Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19624668A DE19624668A1 (de) | 1996-06-20 | 1996-06-20 | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| PCT/EP1997/003244 WO1997048397A1 (en) | 1996-06-20 | 1997-06-20 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE224713T1 true ATE224713T1 (de) | 2002-10-15 |
Family
ID=7797502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97928260T ATE224713T1 (de) | 1996-06-20 | 1997-06-20 | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0912176B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2000512652A (cg-RX-API-DMAC10.html) |
| AT (1) | ATE224713T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU3262497A (cg-RX-API-DMAC10.html) |
| DE (2) | DE19624668A1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK0912176T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2181006T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT912176E (cg-RX-API-DMAC10.html) |
| WO (1) | WO1997048397A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA975443B (cg-RX-API-DMAC10.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
| US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
| DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
| DE19756235A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
| DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| US6291459B1 (en) * | 1998-08-12 | 2001-09-18 | Smithkline Beecham Corporation | Calcilytic compounds |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| DE19908483A1 (de) * | 1999-02-26 | 2000-10-05 | Klinge Co Chem Pharm Fab | Inhibitoren der zellulären Niacinamidmononucleotid-Bildung |
| WO2002013802A2 (en) | 2000-08-11 | 2002-02-21 | Wyeth | Method of treating estrogen receptor positive carcinoma |
| ES2527688T3 (es) | 2000-09-29 | 2015-01-28 | Glaxo Group Limited | Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias |
| EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| CA2601508C (en) | 2005-03-17 | 2012-01-03 | Pfizer, Inc. | Cyclopropanecarboxamide derivatives |
| PE20071159A1 (es) | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
| WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| RU2529468C2 (ru) | 2008-06-24 | 2014-09-27 | Топотаргет А/С | Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида |
| AU2009286604B2 (en) | 2008-08-29 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Novel urea and thiourea derivatives |
| JP2012533530A (ja) | 2009-07-17 | 2012-12-27 | トポターゲット・アクティーゼルスカブ | ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法 |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| MX347889B (es) | 2010-09-03 | 2017-05-17 | Forma Tm Llc * | Compuestos y composiciones novedosos para la inhibición de nampt. |
| WO2012031196A1 (en) | 2010-09-03 | 2012-03-08 | Forma Therapeutics, Inc. | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
| US9676721B2 (en) | 2010-09-03 | 2017-06-13 | Forma Tm, Llc | Compounds and compositions for the inhibition of NAMPT |
| ES2622881T3 (es) * | 2010-09-29 | 2017-07-07 | Intervet International B.V. | Compuestos de N-heteroarilo |
| CN103347860A (zh) | 2010-11-15 | 2013-10-09 | Abbvie公司 | Nampt抑制剂 |
| SG190819A1 (en) | 2010-11-15 | 2013-07-31 | Abbvie Inc | Nampt and rock inhibitors |
| KR20140027366A (ko) | 2011-05-04 | 2014-03-06 | 포르마 티엠, 엘엘씨. | Nampt의 억제를 위한 신규 화합물 및 조성물 |
| US9555039B2 (en) | 2011-05-09 | 2017-01-31 | Forma Tm, Llc. | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) |
| UA114323C2 (uk) | 2012-05-11 | 2017-05-25 | Еббві Інк. | Інгібітори nampt |
| CA2873075A1 (en) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
| CN104271572A (zh) | 2012-05-11 | 2015-01-07 | 艾伯维公司 | 用作nampt抑制剂的噻唑羧酰胺衍生物 |
| EP2847181A1 (en) | 2012-05-11 | 2015-03-18 | AbbVie Inc. | Pyridazine and pyridine derivatives as nampt inhibitors |
| EP2925750A1 (en) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| AU2014285019C1 (en) | 2013-07-03 | 2019-05-02 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| MX2018001979A (es) | 2015-08-18 | 2019-04-25 | Karyopharm Therapeutics Inc | (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer. |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| EP3528850A4 (en) | 2016-10-18 | 2020-06-24 | Seattle Genetics, Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| EP3615081A1 (en) | 2017-04-27 | 2020-03-04 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| WO2019149637A1 (en) | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| CN119775198A (zh) | 2018-05-04 | 2025-04-08 | 治疗方案股份有限公司 | 靶向癌症干细胞的癌症治疗 |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| KR20220110744A (ko) | 2019-11-06 | 2022-08-09 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| US20240376074A1 (en) | 2021-05-13 | 2024-11-14 | Remedy Plan, Inc. | Nampt inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| AU7652391A (en) * | 1990-04-10 | 1991-10-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel pyridine esters |
| US5352684A (en) * | 1990-04-10 | 1994-10-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridines as medicaments |
-
1996
- 1996-06-20 DE DE19624668A patent/DE19624668A1/de not_active Ceased
-
1997
- 1997-06-19 ZA ZA9705443A patent/ZA975443B/xx unknown
- 1997-06-20 JP JP10502317A patent/JP2000512652A/ja not_active Withdrawn
- 1997-06-20 EP EP97928260A patent/EP0912176B1/en not_active Expired - Lifetime
- 1997-06-20 ES ES97928260T patent/ES2181006T3/es not_active Expired - Lifetime
- 1997-06-20 AT AT97928260T patent/ATE224713T1/de active
- 1997-06-20 DE DE69715861T patent/DE69715861T2/de not_active Expired - Lifetime
- 1997-06-20 DK DK97928260T patent/DK0912176T3/da active
- 1997-06-20 PT PT97928260T patent/PT912176E/pt unknown
- 1997-06-20 WO PCT/EP1997/003244 patent/WO1997048397A1/en not_active Ceased
- 1997-06-20 AU AU32624/97A patent/AU3262497A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT912176E (pt) | 2003-01-31 |
| ZA975443B (en) | 1998-02-10 |
| DE19624668A1 (de) | 1998-02-19 |
| AU3262497A (en) | 1998-01-07 |
| ES2181006T3 (es) | 2003-02-16 |
| WO1997048397A1 (en) | 1997-12-24 |
| JP2000512652A (ja) | 2000-09-26 |
| DK0912176T3 (da) | 2003-01-13 |
| DE69715861D1 (de) | 2002-10-31 |
| DE69715861T2 (de) | 2003-06-12 |
| EP0912176B1 (en) | 2002-09-25 |
| EP0912176A1 (en) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
| DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE3751470D1 (de) | Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen. | |
| DE60121808D1 (de) | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE389724T1 (de) | Menschliche dnase i hyperaktive varianten | |
| ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| ATE63748T1 (de) | Enzymwiderstandsfaehige immunomodulatorische peptide. | |
| ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
| ATE300052T1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
| ATE313802T1 (de) | Bestimmung von adrenomedullin-bindenden proteinen | |
| DE69410254D1 (de) | Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente | |
| ATE196083T1 (de) | Verwendung von ferrioxamin-b zur behandlung septischen schocks | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
| ATE251631T1 (de) | Dipohosphonsäuresalze für die behandlung von osteoporose | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| NO972313L (no) | Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| ATE279924T1 (de) | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5- dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose | |
| ATE251462T1 (de) | Verfahren zur behandlung von narbengewebe | |
| DE69431603D1 (de) | Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins | |
| ATE338768T1 (de) | Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression | |
| DE69929683D1 (de) | Antisense modulierung von lfa-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0912176 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |